• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Cabot Corporation

    3/18/25 5:01:33 PM ET
    $CBT
    Major Chemicals
    Industrials
    Get the next $CBT alert in real time by email
    8-K
    CABOT CORP DE MA false 0000016040 0000016040 2025-03-13 2025-03-13

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(D)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): March 13, 2025

     

     

    CABOT CORPORATION

    (Exact Name of Registrant as Specified in Its Charter)

     

     

    DELAWARE

    (State or Other Jurisdiction

    of Incorporation)

     

    1-5667   04-2271897

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    TWO SEAPORT LANE, SUITE 1400,

    BOSTON, MASSACHUSETTS

      02210-2019
    (Address of Principal Executive Offices)   (Zip Code)

    (617) 345-0100

    (Registrant’s Telephone Number, Including Area Code)

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $1 par value per share   CBT   The New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.07

    Submission of Matters to a Vote of Security Holders

    On March 13, 2025, the Company held its annual meeting of stockholders pursuant to notice duly given. The Company’s stockholders voted on the following four proposals and cast their votes as set forth below.

     

      1.

    All of the Board’s nominees for director were elected to the class of directors whose term expires in 2028 by the votes set forth in the table below:

     

         For      Against      Abstain      Broker Non-Votes  

    Michael M. Morrow

         43,809,837        3,473,843        64,826        2,009,120  

    Thierry Vanlancker

         46,730,384        591,628        26,494        2,009,120  

    Michelle E. Williams

         46,416,822        905,987        25,697        2,009,120  

    Frank A. Wilson

         44,906,067        2,412,890        29,549        2,009,120  

    In addition to the directors elected at the meeting to the class of directors whose terms expire in 2028, the terms of office of the following directors continued after the meeting: Juan Enriquez, Sean D. Keohane, William C. Kirby, Raffiq Nathoo, Cynthia A. Arnold, Douglas G. Del Grosso, and Christine Y. Yan.

     

      2.

    The Company’s stockholders submitted the votes set forth in the table below for the approval, on an advisory basis, of the compensation of the Company’s named executive officers:

     

    For:

         46,419,685  

    Against:

         746,567  

    Abstain:

         182,253  

    Broker Non-Votes:

         2,009,120  

     

      3.

    The Company’s stockholders approved the Cabot Corporation 2025 Long-Term Incentive Plan by the votes set forth in the table below:

     

    For:

         43,437,221  

    Against:

         3,796,404  

    Abstain:

         114,881  

    Broker Non-Votes:

         2,009,120  

     

      4.

    The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2025 by the votes set forth in the table below:

     

    For:

         47,699,052  

    Against:

         1,629,992  

    Abstain:

         28,582  

    The proposal to ratify the appointment of Deloitte & Touche LLP was a routine matter and, therefore, there were no broker non-votes relating to that matter.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    CABOT CORPORATION
    By:  

    /s/ Karen A. Kalita

    Name:   Karen A. Kalita
    Title:   Senior Vice President and General Counsel

    Date: March 18, 2025

    Get the next $CBT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBT

    DatePrice TargetRatingAnalyst
    11/11/2024$105.00Neutral → Underweight
    JP Morgan
    4/18/2024Buy → Hold
    Deutsche Bank
    3/27/2024$104.00Buy
    Mizuho
    1/8/2024$90.00 → $87.00Buy → Neutral
    UBS
    6/6/2023$87.00 → $80.00Overweight → Neutral
    JP Morgan
    3/13/2023$94.00Outperform
    Credit Suisse
    11/16/2022$80.00 → $90.00Hold → Buy
    Deutsche Bank
    1/4/2022$75.00 → $70.00Buy
    UBS
    More analyst ratings